NO761087L - - Google Patents
Info
- Publication number
- NO761087L NO761087L NO761087A NO761087A NO761087L NO 761087 L NO761087 L NO 761087L NO 761087 A NO761087 A NO 761087A NO 761087 A NO761087 A NO 761087A NO 761087 L NO761087 L NO 761087L
- Authority
- NO
- Norway
- Prior art keywords
- water
- regulating agent
- soluble
- agent
- bowel
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 20
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 18
- 229910052782 aluminium Inorganic materials 0.000 claims description 15
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 15
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 15
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 14
- 230000001105 regulatory effect Effects 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 239000011358 absorbing material Substances 0.000 claims description 9
- 229920000615 alginic acid Polymers 0.000 claims description 9
- 206010010774 Constipation Diseases 0.000 claims description 8
- 235000010443 alginic acid Nutrition 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 239000001814 pectin Substances 0.000 claims description 8
- 235000010987 pectin Nutrition 0.000 claims description 8
- 229920001277 pectin Polymers 0.000 claims description 8
- 229960000292 pectin Drugs 0.000 claims description 8
- 239000000230 xanthan gum Substances 0.000 claims description 8
- 229920001285 xanthan gum Polymers 0.000 claims description 8
- 235000010493 xanthan gum Nutrition 0.000 claims description 8
- 229940082509 xanthan gum Drugs 0.000 claims description 8
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical class [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims description 7
- 239000000783 alginic acid Substances 0.000 claims description 7
- 229960001126 alginic acid Drugs 0.000 claims description 7
- 150000004781 alginic acids Chemical class 0.000 claims description 7
- 230000000968 intestinal effect Effects 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 239000004067 bulking agent Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000002522 swelling effect Effects 0.000 claims description 4
- 208000019399 Colonic disease Diseases 0.000 claims description 3
- 230000002572 peristaltic effect Effects 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 239000007900 aqueous suspension Substances 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 230000002745 absorbent Effects 0.000 claims 1
- 239000002250 absorbent Substances 0.000 claims 1
- 239000006096 absorbing agent Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 230000008961 swelling Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 239000002244 precipitate Substances 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 10
- 239000008141 laxative Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 229940125722 laxative agent Drugs 0.000 description 5
- 230000002475 laxative effect Effects 0.000 description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical group OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000589636 Xanthomonas campestris Species 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940040387 citrus pectin Drugs 0.000 description 1
- 239000009194 citrus pectin Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002468 fat body Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- -1 iron (III) ions Chemical class 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
Fremgangsmåte til fremstilling av et tarmregulerendeMethod for producing a bowel regulator
middel.medium.
Foreliggende oppfinnelse vedrører en fremgangsmåte til fremstilling av lett administrerbare, vannabsorberende tarmregulerende midler, som oppnår maksimal svellingseffekt bare i det miljø hvor de skal frembringe sin virkning, slike prepara-ter og bruk av visse'svellemidler for fremstilling av laksativer samt metode for regulering av konsistensen til fekalier. The present invention relates to a method for the production of easily administered, water-absorbing bowel regulating agents, which achieve maximum swelling effect only in the environment where they are to produce their effect, such preparations and the use of certain swelling agents for the production of laxatives as well as a method for regulating the consistency to faeces.
Formålet med oppfinnelsen er å tilveiebringe etThe purpose of the invention is to provide a
miQidt tarmregulerende middel som har en stimulerende virkning på den tarmperistaltiske bevegelse ved sin evne til å binde store mengder vann og derved betydelig økning av sitt volum. miQidt bowel regulating agent which has a stimulating effect on the bowel peristaltic movement due to its ability to bind large amounts of water and thereby significantly increase its volume.
Et annet formål med oppfinnelsen er å oppnå lagrings-dyktige tarmregulerende midler som ér veldefinerte og som kan fremstilles uavhengig av klimatiske forandringer og innhøstnings-utbytter som kan ha negativ innvirkning på tilførselen av de naturlig forekommende produkter som vanligvis benyttes. Another purpose of the invention is to obtain storable bowel regulating agents which are well defined and which can be produced independently of climatic changes and harvest yields which may have a negative impact on the supply of the naturally occurring products which are usually used.
Et■annet formål er å oppnå et tarmregulerende middel som kan administreres oralt som en lavviskøs vandig suspensjon og som bare sveller i mage-tarmkanalen og derved positivt påvirker den tarmperistaltiske bevegelse. Another object is to achieve a bowel regulating agent which can be administered orally as a low-viscosity aqueous suspension and which only swells in the gastrointestinal tract and thereby positively affects the intestinal peristaltic movement.
Et ytterligere formål er å tilveiebringe et tarmregulerende middel for bruk ved funksjonelle tykktarmssykdommer og konstipasjon. A further object is to provide a bowel regulating agent for use in functional colon diseases and constipation.
Det er kjent at stillesittende arbeide, liten mosjon, for ren mat med lite fiberinnhold og visse stimulerende midler slik som te og rødvin, skaper konstipasjon eller forstoppelse. It is known that sedentary work, little exercise, too clean food with little fiber content and certain stimulants such as tea and red wine cause constipation or constipation.
Bivirkningene av slik forstoppelse er flere, men her skal bare nevnes inflammatoriske irritasjoner, smertefull flatulent dyspepsi og muligens kreft. The side effects of such constipation are numerous, but only inflammatory irritations, painful flatulent dyspepsia and possibly cancer should be mentioned here.
Kreft i tykktarmen er blitt diagnostisert i et økende antall i de senere år og det har vært sagt at grunnen blant'annet er liten stimulering av tarmen, hovedsakelig avhengig av mangel på grov mat, d.v.s. mat inneholdende celluloseholdige deler og fibre som er vanskelige å fordøye eller endog ufordøye-lige . Colon cancer has been diagnosed in increasing numbers in recent years and it has been said that the reason, among other things, is little stimulation of the intestine, mainly depending on a lack of coarse food, i.e. food containing cellulose-containing parts and fibers that are difficult to digest or even indigestible.
Svellemidler blir idag anbefalt som det mest egnede middel for forstoppelse, og ved behandling av andre sykdommer i tykktarmen, som f.eks.'colon irritabile, diverticulosis og diarré. Bulking agents are today recommended as the most suitable remedy for constipation, and for the treatment of other diseases of the large intestine, such as irritable colon, diverticulosis and diarrhoea.
Ved diarrétiske tilstander samt ved forstoppelse utnyttes midlenes evne til å absorbere vann og derved til å normalisere konsistensen til fekaliene. Ved absorbsjon- av vann økes volumet til tarminnholdet, hvilket øker tarmaktiviteten (peristaltis) og man får en normalisering av uttømmingsfrekvensen. In diarrheic conditions as well as in case of constipation, the ability of the agents to absorb water is utilized and thereby to normalize the consistency of the faeces. When water is absorbed, the volume of the bowel contents is increased, which increases bowel activity (peristalsis) and normalizes the emptying frequency.
Det er tidligere kjent hvordan man skal fremstille laksativer av den såkalte "bulk" type, d.v.s. laksativer som har evne til å svelle i vann og som derved påvirker tarmaktiviteten. Slike laksativer fremstilles fra flere forskjellige, vanligvis naturlig forekommende slimavsondrende midler som derved må gjennomgå en spesiell renseprosess blant annet for å.fjerne fremmedlegemer, fett og mikroorganismer. Disse midler har evne til å holde tilbake store mengder vann og derved gi et stort volum av tarminnholdet. It is previously known how to produce laxatives of the so-called "bulk" type, i.e. laxatives that have the ability to swell in water and thereby affect bowel activity. Such laxatives are made from several different, usually naturally occurring mucus-secreting agents which must therefore undergo a special cleaning process, among other things, to remove foreign bodies, fat and microorganisms. These agents have the ability to retain large amounts of water and thereby provide a large volume of the intestinal contents.
Svellemidler av denne type er imidlertid forbundet med en rekke ulemper. De skal ikke administreres i tørr form fordi det er en stor risiko for at spiserøret og muligens luft-røret vil bli lukket når forbindelsene hurtig sveller i kontakt med den fuktighet som er tilstede i slimhinnene. Et slikt svellemiddel må derfor suspenderes i vann og administreres som en oppløsning eller suspensjon. En for hurtig svelling vil imidlertid oppstå, viskositeten øker og preparatet vil være vanskelig å svelge. Tiden for svellingen er for.kort til å lette en sentral fordeling av medikamenter og laksativer ved et hospital, hvilket er et krav sett fra et rasjonelt synspunkt. However, swelling agents of this type are associated with a number of disadvantages. They should not be administered in dry form because there is a great risk that the esophagus and possibly the trachea will be closed when the compounds rapidly swell in contact with the moisture present in the mucous membranes. Such a bulking agent must therefore be suspended in water and administered as a solution or suspension. Too rapid swelling will, however, occur, the viscosity increases and the preparation will be difficult to swallow. The time for the swelling is too short to facilitate a central distribution of drugs and laxatives at a hospital, which is a requirement seen from a rational point of view.
Tilførselen' av disse naturlig forekommende produkter er dessuten usikker, delvis fordi man må stole på en god høst som kan variere meget eller fullstendig slå feil, og delvis fordi man må transportere dem over lange avstander hvor klimaet kan spille en viktig rolle for deres sluttlige tilstand. The supply of these naturally occurring products is also uncertain, partly because one has to rely on a good harvest which can vary widely or fail completely, and partly because they have to be transported over long distances where the climate can play an important role in their final state .
En ytterligere ulempe er deres følsomhet overfor fuktighet. Dessuten inneholder produktene mange mikroorganismer spesielt spordannende bakterier, hvilket gjør det kostbart og vanskelig å oppnå et rent produkt sett fra et farmasøytisk synspunkt. A further disadvantage is their sensitivity to moisture. In addition, the products contain many microorganisms, especially spore-forming bacteria, which makes it expensive and difficult to obtain a pure product from a pharmaceutical point of view.
Det er dessuten kjent hvordan man kan bruke etyl-hydroksyetylcellulose som et svellemiddel, hvilket middel sies å ha en svellende virkning i mage-tarmkanalen. It is also known how to use ethyl hydroxyethyl cellulose as a bulking agent, which agent is said to have a swelling effect in the gastrointestinal tract.
Det er også kjent hvordan man bruker karboksymetylcellulose som et svellemiddel, men dette har imidlertid de samme ulemper som andre slimaktige eller slimavsondrende midler idet det sveller for hurtig og er således vanskelig å administrere. It is also known how to use carboxymethyl cellulose as a swelling agent, but this however has the same disadvantages as other mucilaginous or mucus-secreting agents in that it swells too quickly and is thus difficult to administer.
Man har nå overraskende funnet at det er mulig å overvinne disse ulemper ved foreliggende oppfinnelse som kjenne-tegnes ved at et vannoppløselig, vannabsorberende materiale fra gruppen bestående av aluminium- og/eller jern-(III)-salter av karboksymetylcellulose, alginsyre, xantangummi eller pektin tilsettes et pH-regulerende middel i en slik mengde at det oppnås en pH-verdi på under 7 i en vandig oppløsning derav. It has now surprisingly been found that it is possible to overcome these disadvantages with the present invention, which is characterized by the fact that a water-soluble, water-absorbing material from the group consisting of aluminum and/or iron (III) salts of carboxymethyl cellulose, alginic acid, xanthan gum or pectin, a pH-regulating agent is added in such an amount that a pH value of below 7 is achieved in an aqueous solution thereof.
Ifølge en foretrukken utførelse av oppfinnelsen tilsettes pH-regulerende midler i en mengde slik at det oppnås en pH-verdi på under 5>fortrinnsvis under 4. According to a preferred embodiment of the invention, pH-regulating agents are added in an amount so that a pH value of below 5>preferably below 4 is achieved.
Ifølge en annen egnet utførelse av oppfinnelsen har det vannoppløselige, vannabsorberende materiale en partikkel-størrelse som i det vesentlige ikke overskrider 0,5 mm for å oppnå- egnede svellebetingelser. According to another suitable embodiment of the invention, the water-soluble, water-absorbing material has a particle size which essentially does not exceed 0.5 mm in order to achieve suitable swelling conditions.
Ifølge en annen, ytterligere egnet utførelse av oppfinnelsen blir det til det vannoppløselige, vannabsorberende materiale tilsatt en organisk syre og et karbonat og/eller et hydrogenkarbonat for oppnåelse av et brusende sluttprodukt når dette oppløses i vann. According to another, further suitable embodiment of the invention, an organic acid and a carbonate and/or a hydrogen carbonate are added to the water-soluble, water-absorbing material to obtain an effervescent end product when this is dissolved in water.
Karboksymetylcellulosen anvendes hensiktsmessig i form av dets natriumsalt hvorved viskositetsgraden til karboksymetylcellulosen ikke har noen betydning hverken på dannelsen av komplekset av aluminium- og/eller jern-(III)-ioner eller på den tarmregulerende virkning, men lav, midlere og høy viskositets-egenskaper kan benyttes. The carboxymethyl cellulose is suitably used in the form of its sodium salt, whereby the degree of viscosity of the carboxymethyl cellulose has no effect either on the formation of the complex of aluminum and/or iron (III) ions or on the bowel regulating effect, but low, medium and high viscosity properties can used.
Aluminium- og jern-(III)-saltene som anvendes i foreliggende oppfinnelse kan lett oppnås ved tilsetning av et aluminium- eller jern-(III)-salt i form av en tørr komponent,, eller vandig oppløsning, eller oppløsning i et organisk oppløs-ningsmiddel slik som isopropanol, etanol, metanol eller formaldehyd, til karboksymetylcellulose, alginsyre, xantatgu-mmi eller pektin eller salter derav i form av en tørr komponent eller vandig oppløsning, isolering av det utfelte kompleks, tørking av dette og eventuelt maling til en partikkelstørrelse på omkring 0,5 mm. The aluminum and iron (III) salts used in the present invention can be easily obtained by adding an aluminum or iron (III) salt in the form of a dry component, or aqueous solution, or solution in an organic solution agent such as isopropanol, ethanol, methanol or formaldehyde, to carboxymethyl cellulose, alginic acid, xantha gum or pectin or salts thereof in the form of a dry component or aqueous solution, isolation of the precipitated complex, drying thereof and optionally grinding to a particle size of around 0.5 mm.
Et tarmregulerende middel ifølge oppfinnelsen kan være i form av et pulver, tabletter, brusende pulvere, brusende A bowel regulating agent according to the invention can be in the form of a powder, tablets, effervescent powders, effervescent
tabletter, granulater, brusende granulater, suspensjoner eller kapsler. Man kan eventuelt også benytte smøremidler, granule-ringsmidler og andre inerte fyllstoffer som i og for seg kjent. tablets, granules, effervescent granules, suspensions or capsules. You can optionally also use lubricants, granulating agents and other inert fillers which are known per se.
Avhengig av graden av funksjonell tykktarmsykdom eller forstoppelse, kan den daglige mengde av det tarmregulerende middel som skal til for en behandling variere, men er vanligvis 3,5 - 14 g/dag, idet en enkelt dose på 355g er effektiv. En enkelt dose på 4,3 g har blitt benyttet under kliniske forsøk og har vist seg å gi en god virkning. Depending on the degree of functional colon disease or constipation, the daily amount of the bowel regulating agent needed for a treatment can vary, but is usually 3.5 - 14 g/day, with a single dose of 355g being effective. A single dose of 4.3 g has been used during clinical trials and has been shown to produce a good effect.
I de nedenstående eksempler er det benyttet karboksy-metylcelluloser av typen lavviskøs "CMC 7 LF", midlere viskøs "CMC 7 MF" og høyviskøs "CMC 7 HF". In the examples below, carboxymethylcelluloses of the low-viscosity "CMC 7 LF", medium-viscosity "CMC 7 MF" and high-viscosity "CMC 7 HF" have been used.
Xantangummi er et anionisk heteropolysakkarid som er dannet ved fermentering av Xanthomonas campestris i en karbo-hydratholdig næringsmiddeloppløsning. Dette polysakkarid har varebetegnelsene "Keltrol R " og "Biopolymer XB-23 Xanthan Gum". Xanthan gum is an anionic heteropolysaccharide that is formed by fermentation of Xanthomonas campestris in a carbohydrate-containing nutrient solution. This polysaccharide has the trade names "Keltrol R" and "Biopolymer XB-23 Xanthan Gum".
Alginsyre eller et salt- derav slik som natriumalginat kan også benyttes ("Below Manucol SS/LH"). Alginic acid or a salt thereof such as sodium alginate can also be used ("Below Manucol SS/LH").
Det pektin som er benyttet i de nedenstående eksempler er sitruspektin. The pectin used in the examples below is citrus pectin.
Eksempel 1Example 1
3,0 kg natriumkarboksymetylcellulose ble oppløst i 72,0 kg destillert vann, hvorved 1,3 kg AlCl^. 2 H20 oppløst i 6,0 kg destillert vann ble tilsatt under omrøring. Det dannet seg med en gang et bunnfall. Bunnfallet ble frafiltrert og vasket med destillert vann. Det ble tørket ved 45°C i et oppvarmingsrom. Sluttproduktet bestående av harde, blekgule klumper, ble oppmalt til en partikkelstørrelse på 0,15 mm. Utbytte: 2,8 kg. Sluttproduktet besto av aluminiumkarboksymetylcellulose inneholdende 3.0 kg of sodium carboxymethyl cellulose was dissolved in 72.0 kg of distilled water, whereby 1.3 kg of AlCl^. 2 H 2 O dissolved in 6.0 kg of distilled water was added with stirring. A precipitate immediately formed. The precipitate was filtered off and washed with distilled water. It was dried at 45°C in a heating room. The final product, consisting of hard, pale yellow lumps, was ground to a particle size of 0.15 mm. Yield: 2.8 kg. The final product consisted of aluminum carboxymethyl cellulose containing
3 % Al.3% Al.
Produktet ble testet med hensyn til dets svelle-kapasitet i vann, kunstig magesaft og kunstig tarmsaft ifølge British Pharm. Codex (1973), side 257, - Ispaghula-skall. Derved ble følgende volumer av pulver eller gel oppnådd i 100 ml væske. Destillert vann 2 ml pulver Kunstig magesaft 13 ml gel Kunstig tarmsaft 100 ml gel. The product was tested for its swelling capacity in water, artificial gastric juice and artificial intestinal juice according to British Pharm. Codex (1973), page 257, - Ispaghula shell. The following volumes of powder or gel were thereby obtained in 100 ml of liquid. Distilled water 2 ml powder Artificial gastric juice 13 ml gel Artificial intestinal juice 100 ml gel.
Ved suspensjon i vann ble det ikke oppnådd noen svelling, mens man i magesaft og fortrinnsvis i tarmsaft fikk en geldannelse. When suspended in water, no swelling was achieved, while in gastric juice and preferably in intestinal juice a gel formation was obtained.
Eksempel 2Example 2
2 kg natriumkarboksymetylcellulose og 1 kg AlCl-^ ble blandet i tørr tilstand og helt i 60 kg destillert vann. Oppløs-ningen ble omrørt i 20 min. og ble deretter hensatt i 15 min. 2 kg of sodium carboxymethyl cellulose and 1 kg of AlCl-^ were mixed in a dry state and poured into 60 kg of distilled water. The solution was stirred for 20 min. and was then set aside for 15 min.
Det dannede hvite bunnfall ble frafiltrert og oppvarmet slik som i eksempel 1. The white precipitate formed was filtered off and heated as in Example 1.
Svelleforsøk:Swelling test:
Eksempel 3 Example 3
Til 3,0 kg natriumkarboksymetylcellulose i 72 kg destillert vann ble det tilsatt en oppløsning av 1,9 kg FeCl-^ . 6H2O i 6 kg destillert vann under omrøring. Det oppnådde bunnfall ble frafiltrert, vasket med destillert vann og tørket. Sluttproduktet besto av jern-(III)-karboksymetylcellulose med et innhold på 7 i? Fe. A solution of 1.9 kg of FeCl-^ was added to 3.0 kg of sodium carboxymethyl cellulose in 72 kg of distilled water. 6H2O in 6 kg of distilled water while stirring. The resulting precipitate was filtered off, washed with distilled water and dried. The final product consisted of iron-(III)-carboxymethylcellulose with a content of 7 in? Fairy.
Svelleforsøk:Swelling test:
Eksempel 4 Example 4
30 g AlCl-j . 6H20 ble oppløst i 270 g metanol. Til denne oppløsning ble det tilsatt 300 g av en 2 % vandig oppløs-ning av NaCMC hvorved det ble oppnådd et hvitt bunnfall som ble frafiltrert og behandlet slik som i eksempel 1. 30 g AlCl-j . 6H 2 O was dissolved in 270 g of methanol. To this solution was added 300 g of a 2% aqueous solution of NaCMC, whereby a white precipitate was obtained which was filtered off and treated as in example 1.
Eksempel 5Example 5
30 g A1C13. 6H20 ble oppløst i 270 g etanol + 50 g destillert vann. Til denne oppløsning ble det tilsatt 300 g av en 2 % vandig oppløsning av NaCMC, hvilket ga et hvitt bunnfall som ble isolert og behandlet slik som i eksempel 1. 30 g of A1C13. 6H 2 O was dissolved in 270 g of ethanol + 50 g of distilled water. To this solution was added 300 g of a 2% aqueous solution of NaCMC, which gave a white precipitate which was isolated and treated as in Example 1.
Eksempel 6Example 6
30 g AlCl-j • 6H20 ble oppløst i 2.70 g isopropanol + 50 g destillert vann. Til denne oppløsning ble det tilsatt 300 g av en 2 % vandig oppløsning av NaCMC. Det dermed oppnådde hvite bunnfall ble isolert og behandlet slik som i eksempel 1. 30 g of AlCl-j • 6H20 were dissolved in 2.70 g of isopropanol + 50 g of distilled water. To this solution was added 300 g of a 2% aqueous solution of NaCMC. The thus obtained white precipitate was isolated and treated as in example 1.
Eksempel 7Example 7
30 g AlClj. 6H20 ble oppløst i 270 g formaldehyd. Til denne oppløsning ble det tilsatt 300 g av en 2 % vandig oppløsning av NaCMC. Det dermed oppnådde hvite bunnfall ble isolert og behandlet slik som i eksempel 1. 30 g of AlClj. 6H 2 O was dissolved in 270 g of formaldehyde. To this solution was added 300 g of a 2% aqueous solution of NaCMC. The thus obtained white precipitate was isolated and treated as in example 1.
Svelleevnen til produktene fra eksemplene 5-8 ble. testet ifølge den ovenfor angitte metode. The swellability of the products from Examples 5-8 was. tested according to the above method.
Eksempel 8 Example 8
250 g 2 % AlCl^. 6H20 ble blandet med 500 g av en250 g of 2% AlCl^. 6H 2 O was mixed with 500 g of a
2 % Na-alginatoppløsning ("Manucol SS/LH") under omrøring. Dette ga et gulbrunt bunnfall som ble isolert og behandlet slik som i eksempel 1. Sluttproduktet besto av aluminiumalginat. 2% Na-alginate solution ("Manucol SS/LH") with stirring. This gave a yellow-brown precipitate which was isolated and treated as in example 1. The final product consisted of aluminum alginate.
Svellingstest:Swelling test:
Eksempel 9 Example 9
En 1 % oppløsning av AlCl^. 6H20 i vann ble fremstilt og pH-verdien ble innstilt til 4,2 under anvendelse av A 1% solution of AlCl^. 6H 2 O in water was prepared and the pH was adjusted to 4.2 using
NaOH. 125 g av én slik oppløsning ble tilsatt til 500 g av en 0,25 % vandig oppløsning av xantangummi ("KeltrolC^"). Det således oppnådde gulhvite bunnfall ble isolert og behandlet slik som i eksempel 1. NaOH. 125 g of one such solution was added to 500 g of a 0.25% aqueous solution of xanthan gum ("KeltrolC^"). The yellow-white precipitate thus obtained was isolated and treated as in example 1.
Svellingstest:Swelling test:
Ekeempel 10 Oak example 10
En 2 % vandig oppløsning av AlCl^. 6H2O ble fremstilt og pH-verdien ble innstilt til 3»9under anvendelse av natriumhydroksyd. 400 g av denne oppløsning ble blandet med 400 g av en 3 % oppløsning av pektin. Dette ga et brunt bunnfall som ble isolert og tørket ved 40°C. A 2% aqueous solution of AlCl^. 6H 2 O was produced and the pH was adjusted to 3.9 using sodium hydroxide. 400 g of this solution was mixed with 400 g of a 3% solution of pectin. This gave a brown precipitate which was isolated and dried at 40°C.
SveIlingsforsøk:Swelling test:
Eksempel 11 Example 11
Ifølge eksempel 1 fremstilte man aluminiumkarboksymetylcellulose under anvendelse av natriumkarboksymetylcellulose med en midlere viskositet. According to example 1, aluminum carboxymethyl cellulose was prepared using sodium carboxymethyl cellulose with a medium viscosity.
Eksempel 12Example 12
Ifølge eksempel 1 fremstilte man aluminiumkarboksymetylcellulose under anvendelse av natriumkarboksymetylcellulose med høy viskositet. According to example 1, aluminum carboxymethyl cellulose was produced using high viscosity sodium carboxymethyl cellulose.
For lettere å bestemme mulige forskjeller i svellings-kapasiteten, ble svellingsforsøket utført under anvendelse av 0,4 g stoff i stedet for 1,0 g. Av sammenligningsgrunner ble det benyttet lavviskøs aluminiumkarboksymetylcellulose. To more easily determine possible differences in the swelling capacity, the swelling test was performed using 0.4 g of material instead of 1.0 g. For comparison purposes, low viscosity aluminum carboxymethyl cellulose was used.
Alle ga 100 ml i kunstig tarmsaft. Viskositeten varierte slik at Al-CMC fremstilt fra høyviskøs Na-CMC ga en- høyere viskositet enn den fremstilt fra midlere viskøst Na-CMC og den fremstilt fra lavviskøst Na-CMC ga den laveste viskositet. All gave 100 ml of artificial intestinal juice. The viscosity varied so that Al-CMC produced from high-viscosity Na-CMC gave a higher viscosity than that produced from medium-viscosity Na-CMC and that produced from low-viscosity Na-CMC gave the lowest viscosity.
Det ble utført en svellingstest i kunstig magesaft under anvendelse av 1,0 g stoff. A swelling test was carried out in artificial gastric juice using 1.0 g of substance.
Laksativvirkningen under anvendelse av et laksativ fra eksempel- 1 hår vært undersøkt og ble dermed sammenlignet med et laksativ av pulverisert isp'agula-skall. Forsøkene ble utført på rotter som ble foret med 1 vekt-$ og 5 vekt-$ A1V-CMC i normal-for, og 5 vekt-% av pulverisert ispagula-skall i normal-for. The laxative effect using a laxative from example 1 hair has been investigated and was thus compared with a laxative from powdered isp'agula shell. The experiments were performed on rats that were fed 1 wt-$ and 5 wt-$ A1V-CMC in normal feed, and 5 wt% of powdered ispagula shell in normal feed.
Totale fekalier i g7~som ble oppsamlet i løpet av 21 forsøks-■ dager, er angitt i nedenstående tabell. Verdiene er midlere verdier. Total faeces in g7~ which were collected during 21 experimental days are given in the table below. The values are mean values.
Som det fremgår fra tabellen ble det oppnådd fullstendig sammenlignbare laksativvirkninger med aluminiumkarboksymetylcellulose og pulverisert ispagulaskall, hvorved det har vært mulig å eliminere ulempene med ispagulapulver. As can be seen from the table, completely comparable laxative effects were achieved with aluminum carboxymethyl cellulose and powdered ispagula husk, whereby it has been possible to eliminate the disadvantages of ispagula powder.
Laksativets partikkelstørrelse kan variere avhengig av administrasjonsmåten. Denne partikkelstørrelse kan således være 0,2-0,5 mm blandet med for.i tørr form, og 0,1-0,2 mm suspendert i vann. The laxative's particle size may vary depending on the method of administration. This particle size can thus be 0.2-0.5 mm mixed with for. in dry form, and 0.1-0.2 mm suspended in water.
Claims (12)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE7504053A SE7504053L (en) | 1975-04-09 | 1975-04-09 | SWELLING AGENT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO761087L true NO761087L (en) | 1976-10-12 |
Family
ID=20324217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO761087A NO761087L (en) | 1975-04-09 | 1976-03-29 |
Country Status (12)
| Country | Link |
|---|---|
| JP (1) | JPS51142546A (en) |
| AU (1) | AU1275176A (en) |
| BE (1) | BE840555A (en) |
| DE (1) | DE2614455A1 (en) |
| DK (1) | DK153276A (en) |
| FI (1) | FI760960A7 (en) |
| FR (1) | FR2306706A1 (en) |
| LU (1) | LU74731A1 (en) |
| NL (1) | NL7603360A (en) |
| NO (1) | NO761087L (en) |
| NZ (1) | NZ180551A (en) |
| SE (1) | SE7504053L (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3332301A1 (en) * | 1983-09-07 | 1985-03-21 | Algina AG, Zug | METAL SALTS AND METAL MIXED SALTS OF POLYMERS, ANIONIC CARBONIC ACIDS AND / OR THEIR SULFURIC ACID ESTERS, METHOD FOR THE PRODUCTION THEREOF, THE MEDICINAL PRODUCTS CONTAINING THEM AND THEIR USE |
| JPS63165325A (en) * | 1986-12-27 | 1988-07-08 | Snow Brand Milk Prod Co Ltd | Intestine-conditioning agent |
| DK179687D0 (en) * | 1987-04-08 | 1987-04-08 | Farma Food As | PREPARATION |
| CN1777434A (en) * | 2003-04-25 | 2006-05-24 | 亘起物产有限会社 | Constipation prevention and improvement agent |
-
1975
- 1975-04-09 SE SE7504053A patent/SE7504053L/en unknown
-
1976
- 1976-03-29 NO NO761087A patent/NO761087L/no unknown
- 1976-03-31 NL NL7603360A patent/NL7603360A/en not_active Application Discontinuation
- 1976-03-31 DK DK153276A patent/DK153276A/en not_active IP Right Cessation
- 1976-04-03 DE DE19762614455 patent/DE2614455A1/en active Pending
- 1976-04-07 AU AU12751/76A patent/AU1275176A/en not_active Expired
- 1976-04-08 FR FR7610341A patent/FR2306706A1/en active Granted
- 1976-04-08 NZ NZ180551A patent/NZ180551A/en unknown
- 1976-04-08 FI FI760960A patent/FI760960A7/fi not_active Application Discontinuation
- 1976-04-09 BE BE165984A patent/BE840555A/en unknown
- 1976-04-09 JP JP51040202A patent/JPS51142546A/en active Pending
- 1976-04-09 LU LU74731A patent/LU74731A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NL7603360A (en) | 1976-10-12 |
| FR2306706A1 (en) | 1976-11-05 |
| NZ180551A (en) | 1978-04-28 |
| DK153276A (en) | 1976-10-10 |
| FI760960A7 (en) | 1976-10-10 |
| AU1275176A (en) | 1977-10-20 |
| DE2614455A1 (en) | 1976-10-28 |
| LU74731A1 (en) | 1977-02-04 |
| JPS51142546A (en) | 1976-12-08 |
| SE7504053L (en) | 1976-10-10 |
| BE840555A (en) | 1976-10-11 |
| FR2306706B1 (en) | 1979-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI289460B (en) | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture | |
| JPH0745521B2 (en) | Antihypertensive agent having antihypertensive effect | |
| JP2002138035A (en) | Method for sealing capsule | |
| JPH08504214A (en) | Konjac glucomannan readily available as a modified release excipient | |
| EP0236124A2 (en) | Beta-d-glucan, and its production and uses | |
| CN113521305A (en) | Propolis alcohol extract-cyclodextrin-chitosan-mucin sustained-release gel as well as preparation method and application thereof | |
| NZ214943A (en) | Preparing sucrose encrusted methylcellulose particles for use in bulk laxatives | |
| WO2020113812A1 (en) | Nadh-containing biological high-molecular-weight nanosphere, preparation method for same, and applications thereof | |
| JP4321007B2 (en) | Polysaccharide complex and method for producing the same | |
| WO1997006808A1 (en) | Combination osmotic and bulk forming laxatives | |
| CN113841904A (en) | Preparation method and application of konjac gel powder | |
| JPS61205213A (en) | Medicine composition | |
| CN104324016A (en) | Soft-capsule wall material formula | |
| Nep et al. | Pharmaceutical properties and applications of a natural polymer from Grewia mollis | |
| CN106188324B (en) | Hydroxyethyl pachyman preparation and its as sustained release tablets framework material application | |
| NO159697B (en) | PROCEDURE FOR THE PREPARATION OF NEW COMPLEXES OF CARRAGEENAN AND EMEPRON, DOXYCYCLIN OR PROPRANOLOL. | |
| US4225614A (en) | Method of treatment for mucocutaneous herpes simplex infections | |
| JPH07508532A (en) | Compositions for controlled release of active substances as well as methods of preparing such compositions | |
| KR100644149B1 (en) | An evacuant | |
| EP1322293B1 (en) | Modified release formulation | |
| Madhulika et al. | A review on natural and synthetic polymers employed in the formulation of oral disintegrating tablets | |
| JPS63185352A (en) | Oligosaccharide-containing food | |
| CN113603808B (en) | Modified algin, preparation method and application thereof in preparation of medicine for promoting gastrointestinal peristalsis | |
| JPH0586227A (en) | Water-soluble dietary fiber complex and food composition containing the same | |
| CN117159448A (en) | Loratadine oral gel preparation, preparation method and application thereof |